Clinical trial
Phase II Study of Single Agent OSI-7904L in Patients With Gastric or…
NCT00073502 · OSI Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00073502 |
|---|---|
| Title | Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer |
| Official title | A Phase II Study of Single Agent OSI-7904L In Patients With Locally Advanced or Metastatic Adenocarcinoma Of the Stomach or Gastroesophageal Junction |
| Lead sponsor | OSI Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma |
| Intervention type | Drug |
| Interventions | OSI-7904L |
| Enrollment | 43 |
| Start date | Oct 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | Nov 25, 2003 |
| Last update posted | Feb 22, 2006 |
| Countries | Belgium, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: